respectively. Isoprenalin-induced (5-30 g) vasodilatation was 43 8 2% lower in SHR compared to WKY and GW1929 enhanced this vasodilatation by 55 8 2%. In SHR kidney, GW1929 enhanced expression of PPAR ␥ mRNA (34 8 1%) but reduced that of GRK-2 (31 8 3%). Conclusion: We suggest that downregulation of PPAR ␥ but upregulation of GRK-2 increases blood pressure and impaired renal vascular reactivity in SHR and that PPAR ␥ -mediated improvement in hypertension may involve transcriptional regulation of GRK-2 function.
Introduction
G protein-coupled receptors (GPCRs) are regulated by multiple mechanisms that serve to adapt their signaling ability to a constantly changing environment. One of the most rapid mechanisms modulating agonist-activated receptors is phosphorylation by G protein-coupled receptor kinases (GRKs) resulting in uncoupling of the GPCR-mediated transduction process [1] . This phenomenon termed desensitization involves several processes including phosphorylation, sequestration/internalization and degradation of receptor protein [1] . Seven distinct GRKs (GRK1-7) have been identified to date [2] . GRKs 1 and 7 belong to the rhodopsin family, GRKs 2 and 3 belong to ␤ -adrenergic receptor kinase ( ␤ ARK) family and GRKs 4, 5 and 6 belong to the GRK4 family [1] [2] [3] [4] . The phosphorylation of GPCRs, including ␤ -adrenergic receptors, leads to the binding of a member or members of the arrestin family and uncoupling of the receptors from the G protein complex decreasing its functional response.
Because of the lack of drug acting directly on GRKs, the physiological function of GRK-2 ( ␤ ARK) is still largely unknown. The role of GRK-2 in the pathology of hypertension has long been postulated and special emphasis was given to its function in cardiac development and its role in regulating cardiac ␤ -adrenergic response. The fundamental role of GRK-2 in cardiac development was confirmed in 1996 [5] . Accordingly, transgenic mice overexpressing either ␤ ARK1 or a peptide inhibitor of ␤ ARK1 in the heart demonstrated that the activity of the kinase significantly contributes to the regulation of myocardial contractility [6] . Similarly, Eckhart et al. [7] showed that vascular overexpression of GRK-2 attenuated ␤ -agonist-stimulated vasodilatation. This observation was corroborated by recent works suggesting that embryonic developmental abnormalities following cardiac-specific ablation of GRK-2 may be attributable to the extracardiac effect of GRK-2 [8] . Increased expression and activity of GRK-2 have been reported in both hypertensive subjects [9, 10] and in animal models of hypertension [11] . Penela et al. [12, 13] showed in an aortic smooth muscle cell line that physiological vasoconstrictors markedly enhanced GRK-2 promoter activity resulting in increased GRK-2 mRNA expression suggesting that the expression of GRK-2 is strongly controlled at the transcriptional level.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear receptor superfamily and consist of three isoforms named PPAR ␣ , PPAR ␦ (or ␤ ), and PPAR ␥ . PPAR ␥ is expressed in adipose tissue, endothelial cells, and vascular smooth muscle cells [14] . The role of PPAR ␥ in vascular function has been studied extensively in diabetics [15] as well as in nondiabetics [16] and convincing evidence emerged that PPAR ␥ activation contributes to vascular function [17] .
Involvement of PPAR ␥ in modulating renal vascular function is less well characterized. Previously, we have shown that PPAR ␥ ligand mediated improvement in renal vascular reactivity in a disease model like glycerolinduced acute renal failure [18, 19] . Similarly, Efrati et al. [20] reported PPAR ␥ ligand-mediated improved renal vascular function and suggest that PPAR ␥ effect in the kidney extends beyond glycemic and lipidemic control. This effect is probably via transcriptional regulation of vasoactive components such as catecholamine ( ␤ -adrenergic receptor), angiotensin II (AT 1 receptor), and endothelin-1 (ET A receptor) that works as GPCRs [21] . PPAR ␥ ligands may also potentiate ␤ -adrenergic vasodilatation via activation of Raf/MEK/ERK1/2 signaling pathways [22] where activated ERK1/2 reduced GRK-2 activity [23, 24] and, therefore, plays an important role in GPCR signaling cascade. Although the connection between PPAR ␥ and GRK-2 has never been examined the possibility of PPAR ␥ influencing GRK-2 was never excluded either. At the same time, numerous studies demonstrated the possibility that PPAR ␥ transcriptionally regulates the regulators of G protein signaling (RGS) molecules [25, 26] opening up the possibility of PPAR ␥ -dependent regulation of GRK-2 (also an RGS family of protein). In this study, we have tested the hypothesis that PPAR ␥ ligandmediated improvement in blood pressure and renal vascular reactivity may be attributed to a transcriptional effect of PPAR ␥ on GRK-2 expression. We, therefore, activated PPAR ␥ in hypertensive rats to examine the association of improvement in blood pressure/renal vascular reactivity with that of GRK-2 expression.
Materials and Methods
Male (300-350 g, Harlan) WKY and SHR rats were divided into groups: control and treatment (n = 6-8 rats/group). Treatment group received 0.5 mg/kg of GW1929, an orally active PPAR ␥ ligand, for 2 months while control rats received an equal amount of vehicle (saline). Rats were housed in controlled environment with a 12-hour light and dark cycle and free access to food and water. Systolic blood pressure (SBP) was measured before and 2 months after the treatment period using tail cuff plethysmography (Apollo 179; IITC, Woodland Hills, Calif., USA).
Whole Kidney Perfusion
At the end of the treatment, rats were anesthetized with pentobarbital (40 mg/kg, i.p.) and whole kidney perfusion was determined using a laser scanner (Moor Instrument, Axminster, UK). A mid-ventral incision approximately 5 cm long was then made and the abdomen was kept open using a clamp. Both right and left kidneys were identified and cleaned gently with a saline-soaked cotton bud to separate them from any surrounding tissues. A laser scanner was positioned directly over a set area covering both kidneys and programmed using the software program attached to the laser scanner camera. Three repetitive scans were performed and the mean value determined for each kidney. Renal perfusion was expressed as perfusion units per unit area of kidney.
Rat Isolated Perfused Kidney Preparation
Immediately after determination of whole kidney perfusion, isolated perfused kidney was used to measure renal vascular responses to vasoconstrictors and vasodilators. While still under anesthesia, the left renal artery was cannulated through the ab-dominal aorta and the kidney was perfused by means of a peristaltic pump (model 7515-10, Masterflex cartridge pump, Cole Parmer Instrument, Vernon Hills, Ill., USA) with warmed (37 ° C), oxygenated (95% O 2 and 5% CO 2 ) Krebs-Henseleit buffer composed of 118 m M NaCl, 25 m M NaHCO 3 , 1.9 CaCl 2 , 1.19 MgSO 4 , 4.75 KCl, 1.19 KH 2 PO 4 , and 11.1 m M dextrose (pH 7.2). The flow of perfusate was adjusted in each kidney to obtain a perfusion pressure of 80-120 mm Hg. Mean flow rate was maintained within 8.5-13 ml/min. The inferior vena cava was cut to allow the flow of perfusate and the kidney was removed from the surrounding fat and placed in an organ chamber prewarmed at 37 ° C. The perfusion pressure was monitored constantly by means of a transducer (Transbridge, model TBM-4, World Precision Instrument, Sarasota, Fla., USA) which was connected to a computer by a signal manifold (model DI-720 and DI-205, DataQ Instruments). Because flow was maintained at a constant rate, change in perfusion pressure was used as an index of renal vascular resistance, an increase in perfusion pressure indicating vasoconstriction while a reduction indicates vasodilatation. To determine vasodilator responses baseline perfusion pressure was elevated with phenylephrine (PE; 100 M ) in the buffer before adding the vasodilator agents. All responses were measured as the differences between the minimum pressure and the peak responses (for vasoconstriction) or the difference between the maximum pressure with PE (100 g) and the lowest response (for vasodilatation). Renal vascular response to PE (100 g), acetylcholine (Ach; 30-300 g), sodium nitroprusside (SNP; 5-30 g), and isoprenaline (5-30 g) was determined.
GRK-2 and PPAR ␥ Gene Expression by RT-PCR
Whole kidney homogenates were prepared by homogenizing kidney tissues in RIPA buffer containing protease inhibitor (SC 24948; Santa Cruz Biotechnology, Santa Cruz, Calif., USA). The homogenate was processed to isolate total RNA using the RNeasy Mini kit from Qiagen (Valencia, Calif., USA) following the manufacturer's instructions. Total RNA was quantified and 100 ng of the RNA was reverse transcribed to synthesize cDNA using ReactionReady first strand cDNA synthesis kit (Cat. No. C-03) from Super Array Bioscience (Frederick, Md., USA). The cDNA was then amplified using SYBR Green (Cat. No. PA-011) real-time PCR master mix from SA Bioscience in Bio-Rad iCycler real-time PCR equipment. Rat GRK-2 (Cat. No. PPR45759A) and PPAR-␥ (PPR47599A) specific primer sets were used (SA Bioscience) together with a primer set for GAPDH (PPR06557A) as the housekeeping gene for standardization. Each PCR amplification was performed in triplicate wells following PCR conditions prescribed for the SYBR Green PCR master mix by the manufacturer: 95 ° C for 15 min followed by 40 cycles of 95 ° C for 30 s, 55 ° C for 30 s and 72 ° C for 30 s. A melting curve analysis was performed immediately after PCR cycles to assure that there were no primer dimers. Negative PCR controls including omission of reverse transcriptase or omission of cDNA or primers were used to validate each batch of template before use. Individual data were adjusted with GAPDH value and expressed as ⌬ ⌬ ct.
Statistical Analysis
Response to agonists was expressed as peak change in perfusion pressure from their basal values. Data were presented as mean 8 SEM and comparisons were made within each group and between groups using ANOVA and Student's t test for significant differences. ANOVA was also used to determine differences in blood pressure and whole kidney perfusion values that were compared between groups while gene expression values were expressed as fold change. In all cases p ^ 0.05 was considered significant. Figure 1 illustrates that baseline SBP in SHR rats was 116 8 7% higher than that of the WKY rats (WKY: 81 8 11 mm Hg; SHR: 176 8 6 mm Hg). After a study period of 2 months, SBP in untreated SHR rose to 201 8 6 mm Hg but was reduced by 20 8 1% in GW1929-treated rats (p ! 0.05). Similarly, whole kidney perfusion ( fig. 2 ) was significantly lower in SHR rats compared to that of WKY rats (WKY: 2.22 8 0.07 perfusion units/unit area; SHR: 1.7 8 0.08 perfusion units/unit area). PPAR ␥ induction by GW1929 enhanced whole kidney perfusion in both WKY and SHR rats by 15 8 0.5% (p ! 0.05) and 61 8 3% (p ! 0.01), respectively.
Results

Effects of PPAR ␥ Induction on SBP and Whole Kidney Perfusion
Effect of GW1929 on Renal Vasoconstriction
Basal perfusion pressure in the kidneys isolated from SHR rats was 29 8 2% (p ! 0.05) higher than that in WKY rats (WKY: 100 8 4 mm Hg; SHR: 129 8 11 mm Hg) ( fig. 3 ) , whereas in the GW1929-treated SHR group (102 8 8 mm Hg) it was similar to that of WKY rats. The addition of PE (100 g) in the perfusate increased perfusion pressure in the kidneys from all groups. This vasoconstriction was 29 8 1% (p ! 0.05) higher in kidneys 
Effect of GW1929 on Endothelium-Dependent and Endothelium-Independent Renal Vasodilatation
We tested both endothelium-dependent (Ach) and endothelium-independent (SNP) vasodilatation in the isolated kidney from WKY and SHR rats with or without PPAR ␥ induction. Ach-induced vasodilatation was reduced by 46 8 2% (p ! 0.05) in SHR kidney compared to those from WKY rats (WKY: 24-55%; SHR: 12-18%) ( fig. 4 ) . GW1929 prevented this fall in Ach vasodilatation by maintaining vasodilatation to a level that is similar to that in WKY rats. Similarly, SNP vasodilatation was at- 
Effect of GW1929 on ␤ -Adrenergic StimulationMediated Renal Vasodilatation
We examined the vasodilator responses to isoprenaline as a representative of ␤ -adrenergic stimulation where GRK-2 has been shown to have a profound regulatory effect. Isoprenaline-induced vasodilatation ( fig. 6 ) was significantly lower (43 8 2%; p ! 0.02) in kidneys from SHR rats than in WKY rats (WKY: 13-42%; SHR: 6-27%). PPAR ␥ ligand GW1929 enhanced vasodilatation in SHR by 55 8 2% (p ! 0.01) to a level similar to that of WKY rats.
Effect of GW1929 on PPAR ␥ and GRK-2 Gene Expression in the Kidney
RT-PCR results showed that PPAR ␥ mRNA was 34 8 2% (p ! 0.05) lower ( fig. 7 a) and GRK-2 mRNA was 69 8 6% (p ! 0.05) higher ( fig. 7 b) in kidneys from SHR rats compared to kidneys from WKY rats. GW1929 significantly enhanced PPAR ␥ mRNA expression (34 8 1%) but attenuated GRK-2 mRNA expression (31 8 3%) in SHR but not in WKY rats translating into a 2.4-fold increase in PPAR ␥ gene expression in SHR after GW1929 treatment but a 17.8-fold reduction in GRK-2 expression in SHR.
Discussion
We have shown in this study that GW1929, an orally active PPAR ␥ ligand, prevented the increase in SBP in SHR. GW1929 treatment also enhanced whole kidney perfusion in hypertensive rats confirming the role of PPAR ␥ in cardiovascular regulation. The most interesting observation from this study was the relationship observed between PPAR ␥ and GRK-2, which suggests that PPAR ␥ -mediated improvement in vascular function may involve the GRK-2 gene. This observation was accompa- nied by attenuation of vasoconstrictor response to PE but enhancement of both endothelium-dependent and endothelium-independent vasodilatation in hypertensive rats. PPAR ␥ is expressed in both endothelial cells and vascular smooth muscle cells making it possible that this receptor plays a role in regulating vascular tone and blood pressure [14, [27] [28] [29] [30] . Indeed, PPAR ␥ agonists including thiozolidinediones lower blood pressure in experimental hypertension, an effect that is at least partially independent of their insulin-sensitizing effect [31] [32] [33] [34] . Similarly, in transgenic hypertensive mice, rosiglitazone improved relaxation of carotid arteries to Ach suggesting that the blood pressure-lowering effect of thiozolidinediones may be due to their direct impact on blood vessels [35] . To date, the underlying mechanisms are still under investigation. PPAR ␥ activation may regulate blood pressure via modulation of endothelial vasoactive factors such as endothelin-1, prostacyclin, and nitric oxide. PPAR ␥ may also directly reduce vascular smooth muscle cell tone through downregulation of angiotensin II receptor 1 [36] . It is also hypothesized that at baseline PPAR ␥ suppresses gene expression in vascular cells to contribute to the maintenance of normal blood pressure [37] . Therefore, a reduced PPAR ␥ may lead to a hypertensive phenotype similar to what we observed in this study. Interestingly, a majority of the vasoactive components that seem to be influenced by PPAR ␥ mediate their effects through GPCR and, therefore, GRK-dependent regulation may also contribute to vascular tone. Conversely, PPAR ␥ -mediated vascular regulation may also be involved in regulating GRK activity. The mechanism by which PPAR ␥ ligands provide renoprotection is not totally clear at present. Identification of functional PPAR ␥ receptors in renal glomerular and tubular tissues besides vascular tissues has raised the possibility that both systemic and vascular responses are involved in PPAR ␥ -mediated renal protection [38, 39] . A considerable number of animal and human studies have shown that all PPAR ␥ ligands are capable of producing small but significant changes in blood pressure level and their actions such as improvement in endothelial function, attenuation of sympathetic overactivity, or reduction of intracellular calcium content in vascular smooth muscle cells could be responsible for this effect [40] . Since renal perfusion is a direct reflection of afferent arteriolar pressure or SBP, a reduced SBP would automatically translate into an enhanced renal perfusion and this was a crucial observation in this study. Our data is in agreement with earlier animal [41, 42] and human studies [43] [44] [45] that showed a significant blood pressure reduction and renoprotection by PPAR ␥ ligands.
In this study, we proposed another modality for PPAR ␥ -mediated improvement in renal vascular function: PPAR ␥ activation inhibits GRK-2. The role of GRK-2 in hypertension has been studied extensively because of the observation of increased GRK-2 protein and mRNA expression in hypertension and its role in attenuating ␤ -adrenergic vasodilator response. Experimental studies also show that vascular overexpression of GRK-2 in transgenic mice attenuates ␤ -adrenergic receptor signaling and increased resting blood pressure [7] . At the same time, Ramos-Ruiz et al. [13] showed that physiological vasoconstrictors increased GRK-2 promoter activity of the GRK-2 gene transfected in human aortic smooth muscle cell line suggesting a role for GRK-2 in vascular function. It has been shown earlier that PPAR ␥ can modulate the expression and activity of major endogenous vasoconstrictors such as angiotensin II, endothelin-1, thromboxane as well as their GPCRs. Therefore, it is possible that PPAR ␥ may also have a transcriptional influence on GRKs that are the principal regulators of GPCRs. There is no evidence so far that PPAR ␥ may have a direct influence on GRK-2 gene expression, although indirectly it may. PPAR ␥ ligands have been shown to activate Raf-1/MEK/ERK 1/2 pathway while activated ERK1/2 has been linked to enhanced GPCRmediated response. Interestingly, several reports confirmed that ERK1/2 phosphorylates GRK-2 leading to a reduced GRK-2 activity and downregulation of GRK-2 protein expression [23, 24] . In this study, we have shown that PPAR ␥ -mediated improvement in blood pressure and vascular reactivity may be a direct influence of GRK-2 inhibition. This notion is based on our observation that reduced PPAR ␥ expression in hypertension is associated with increased GRK-2 gene expression, which suggests that PPAR ␥ may have a negative regulation on GRK-2 gene. Therefore, PPAR ␥ activation will reduce GRK-2 and this may be the mechanism for PPAR ␥ ligand-mediated reduction in blood pressure and improvement in vascular reactivity in the hypertensive rats. This hypothesis is further strengthened by our observation that PPAR ␥ activation is associated with a reduced GRK-2 gene expression. These observations led to the possibility that PPAR ␥ transcriptionally regulates GRK-2 gene expression. This notion is underscored by the fact that all the GRKs belong to the RGS family of proteins. Therefore, the presence of a common RGS protein binding domain [46] in GRK-2 gene raised the possibility of regulation by PPAR ␥ since PPAR ␥ has been shown to regulate some other RGS (RGS-2) during adipocyte differentiation [26] . Our findings of reduced GRK-2 mRNA in GW1929-treated SHR comply with this notion and suggest that PPAR ␥ has a transcriptional effect on GRK-2 gene.
In summary, these results suggest that downregulation of PPAR ␥ coupled with upregulation of GRK-2 may be responsible for hypertension and PPAR ␥ ligand-mediated reduction in blood pressure and improved vascular function in SHR may involve transcriptional regulation of GRK-2.
